Tags » ADT

Autodesk 2017 Release Information

Many people are now aware that Autodesk has released the 2017 version of its various software packages.  There are many great blog posts about the enhancements in the packages and I really like some of those enhancements.  156 more words


SEC Charges Research Analyst With Insider Trading on Mother's Brokerage Account

The U.S. Securities and Exchange Commission (SEC) recently announced insider trading charges against a research analyst who allegedly reaped over $1.5 million in February via trades he made in his mother’s brokerage account. 220 more words


Better cancer control with radiation vs. surgery in high-risk patients

Researchers at the University of Alabama at Birmingham assigned high-risk patients to receive either external beam radiation therapy with androgen deprivation therapy (RT + ADT) or to receive surgery (RP) with or without adjuvant/salvage radiation. 638 more words


ADT and the risk for depression

It will come as no great surprise to most readers of this blog that androgen deprivation therapy (ADT) used in the treatment of  men with progressive forms of prostate cancer comes with a significant risk for depression (as well as other effects on cognitive function). 719 more words


New immunotherapeutics aren't working well when combined with standard forms of care

A newly published article in the journal Science Translational Medicine has questioned the merits of treating prostate cancer patients with immunotherapies while they are simultaneously being treated with medical forms of castration (androgen deprivation therapy or ADT), chemotherapy, and/or radiation therapy. 527 more words


ADT + bevacizumab as first-line treatment of recurrent prostate cancer

Data from a small, randomized, Phase II, clinical trial have suggested a possible role for bevacizumab (Avastin) in the treatment of men with recurrent prostate cancer along with androgen deprivation therapy (ADT). 592 more words


Apollo Global Gets Higher Price Target, but No Respect

Publicly traded private equity firm Apollo Global Management Inc. (NYSE: APO) received a boost to its price target Tuesday morning when analysts at Jefferies raise the target from $17 to $20 a share while maintaining a Buy rating on the stock. 492 more words